Association of Serotonergic Pathway Gene Polymorphisms With Behavioral Parameters in Patients With Opioid Dependence

Siddharth Sarkar 1, Renu Singh 2, Arundhati Sharma 2, Muzaffar A. Pandit 1, Ranjan Gupta 2, Deepika Singhal 2, Raka Jain 1, Yatan P. Balhara 1

1. National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, IND 2. Department of Anatomy, All India Institute of Medical Sciences, New Delhi, IND

Corresponding author: Siddharth Sarkar, sidsarkar22@gmail.com

Abstract

Background and aims
Opioid dependence is a chronic, relapsing substance use disorder with a multifactorial etiology, including a genetic component. Serotonin pathway gene polymorphisms have been an important focus of research for psychiatric disorders, including substance use disorders. This study aimed to identify the association of serotonin pathway gene polymorphisms with self-harm, depressive symptoms, impulsiveness, and aggression in patients with opioid dependence.

Method
The study group comprised 366 subjects with opioid dependence and 200 healthy volunteers. Patients were assessed for a history of self-harm, depressive symptoms, impulsiveness, and aggression using standard tools. Genomic DNA was used for genotyping of four polymorphisms - 5-HTTLPR, STin2 VNTR, TPH1 A218C, and TPH2 G703T.

Results
The short allele of 5-HTTLPR polymorphism showed a significant difference between cases (59.8%) and controls (40.1%) (p=0.001) and revealed an association with age at opioid dependence (p=0.033). There was a borderline significance of the short allele of 5-HTTLPR with the duration of opioid use (p=0.061) and non-plan impulsivity (p=0.076), suggesting a role of 5-HTTLPR in the susceptibility of opioid dependence. The other markers did not differ between cases and controls. However, the STin2A polymorphism revealed a significant association with anger scores, which may indicate its role in aggressive behavior.

Conclusions
The present study, the first of its kind, suggests an association of 5-HTTLPR polymorphism with opioid dependence and STin2A polymorphism with aggressive behavior among opioid-dependence patients, signifying the role of these markers in our patient population.

Categories: Genetics, Psychiatry, Substance Use and Addiction
Keywords: impulsiveness, pcr, polymorphism, serotonin, opioid dependence

Introduction
Substance use disorders are among the more common psychiatric disorders worldwide [1]. Globally, about 652,000 people aged 12 years or older have had heroin use disorder, and almost one-fourth of the people who use heroin become addicted. The death rate due to heroin consumption in the US increased from 5,925 in 2012 to 8,257 in 2013 [2]. In India, the prevalence of opioids, cannabis, and alcohol is 0.7%, 3.0%, and 21.4%, respectively [3]. Among the opioid users, 22.3% are dependent users [3]. A recent survey in India published in 2019 has shown that the absolute number of individuals dependent on opioids in India has increased by more than five times over a period of 15 years [3-4]. Substance use disorders are associated with a considerable burden on the healthcare system [5]. Several studies have implicated the role of substance use in the occurrence of self-harm behaviors, depressive symptoms, impulsiveness, and aggression [6-10].

Studies have reported on the association of polymorphisms of serotonergic pathway genes in substance use disorders [11-12]. Serotonin transporter (Solute Carrier Family 6 Member 4 [SLC6A4]/5-HTT) is a sodium-dependent transporter localized at the presynaptic neuronal membranes, involved in the recycling of serotonin between the synapse and the neuronal cell. The serotonin transporter-linked promoter region (5-HTTLPR) and STin2 Variable Number Tandem Repeat (VNTR) polymorphisms of the SLC6A4 gene have been reported to be associated with the risk of developing substance use disorders, as these polymorphisms are...
known to regulate the transcriptional activity of the SLC6A4 gene [13-14]. Serotonin is a crucial neurotransmitter that has a significant role in mood regulation, and low serotonin levels in the brain are associated with depression and suicidal attempts. Variants in the serotonin transporter (SLC6A4), i.e. rs25532, 5-HTTLPR, and STin2 VNTR, are associated with major depression, schizophrenia, and bipolar disorders. 5-HTTLPR polymorphism, present within the promoter region of the SLC6A4 gene, is known to affect its transcriptional activity. The deletion variant or short allele is known to reduce the transcriptional activity of the gene [13]. Studies have also revealed an association of 5-HTTLPR with depression and suicide attempts [15]. STin2 VNTR involves two major alleles (STin2.10 and STin2.12), i.e. 10 and 12 repeats [16]. The biological function of this polymorphism is not yet clear, but STin2.12 has been reported to possess greater transcriptional activity than STin2.10 [17].

Tryptophan hydroxylase (TPH) catalyzes the rate-limiting step in the serotonin (5-HT) synthesis. There are two TPH genes, TPH1 and TPH2, expressed in the central nervous system involved in serotonin metabolism. Studies indicate 5-HT synthesis through TPH2 influences nervous tissues, whereas TPH1 is responsible for the synthesis and action of 5-HT in peripheral organs. Partial impairment of brain 5-HT synthesis caused by polymorphism rs4570625 (G703T) of the gene encoding TPH2 has been linked to several psychiatric phenomena like obsessive-compulsive-disorder, increased aggressiveness, and mood and anxiety disorders, leading to serious conditions like suicidal risks [18-20]. A study reports alteration in anxiety-like behavior in TPH2-deficient mice, which is accompanied by adaptation changes of 5-HT(1A) receptors and the associated signaling pathway [21].

The present study aimed to assess the association of serotonin pathway gene polymorphisms with self-harm, depressive symptoms, impulsiveness, and aggression in patients of opioid dependence in the north Indian population.

Materials And Methods

Setting and participants

The study was in accordance with the declaration of Helsinki and was approved by the institutional ethics committee of the All India Institute of Medical Sciences, New Delhi (IEC-468/07.10.2016, RP-17/2016). The study was conducted at a public-funded addiction treatment center in north India, which is affiliated with a medical school. The center treats patients with a variety of substance use disorders and offers both inpatient and outpatient care facilities. Opioids are the most common substance of use for which treatment is being provided at the center. Treatment is provided in the form of detoxification or opioid substitution treatment based upon clinical considerations and patient preference.

The inclusion criteria (for cases) were males with a diagnosis of opioid dependence (as per International Classification of Diseases (ICD 10) diagnostic criteria), willing to participate in the study, and were not in active withdrawal (reflected by Objective Opioid Withdrawal Scale scores) [22]. Females were excluded, as they comprise about only 2% of the treatment-seeking population at the center. The exclusion criteria were substance dependence (other than opioid/tobacco), severe medical or psychiatric illness, or those who had a current diagnosis of psychotic or mood spectrum disorder as per Mini-International Neuropsychiatric Interview [23] were excluded from the study. The interviews were conducted by trained psychiatrists. We expected depressive symptoms, anxiety symptoms, impulsiveness, and aggression to be present in this population, though we excluded patients with a diagnosable psychotic illness, bipolar disorder, or major depressive episode.

The demographic profile of subjects and controls was noted using a structured questionnaire and the patients with opioid dependence were also interviewed using Hamilton Depression Rating Scale [24], Barratt’s Impulsiveness Scale [25], and Buss Perry Aggression Questionnaire [26].

Genetic analysis

A detailed family history of alcohol use was recorded, and five milliliters of venous blood were drawn in ethylenediaminetetraacetic acid (EDTA) vials from all the participants. Genomic DNA was isolated using the standard salting-out method [27] and processed for polymerase chain reaction (PCR) amplification to screen the polymorphisms 5-HTTLPR, STin2 VNTR, and TPH2(G703T) from the serotonin pathway using the primers and restriction enzymes described previously [28-29]. The details of the same are presented in the Appendix.

Instruments

Barratt’s Impulsiveness Scale [25]

This is a 30-item instrument for the assessment of impulsiveness. Each of the items is rated on a four-point Likert scale from “rarely/never” to “almost/always.” The scale has six first-order factors and three second-order factors. The total score of Barratt’s Impulsiveness Scale has been found to be an internally consistent measure of impulsiveness and has potential clinical utility for measuring impulsiveness.
Buss Perry Aggression Questionnaire [26]

This is a 29-item instrument to assess aggression. Each of the items is rated on a Likert-rated scale from "extremely uncharacteristic of me" to "extremely characteristic of me." The scale has been divided into four factors, namely verbal aggression, physical aggression, anger, and hostility. The scale has good internal consistency and reliability over time. Men score higher on physical aggression, verbal aggression, and hostility as compared to women.

Statistical analysis

The distribution of the quantitative variables as parametric or nonparametric was determined by the Shapiro-Wilk test. Genotype and allele frequencies were compared between subjects using Pearson's chi-square test. Clinical parameters were compared between opioid-dependent individuals with self-harm and those without such harm using Pearson's chi-square test or student's t-test. Correlation of genotypes with factors like age, age at first opioid use, duration of opioid use, age at opioid dependence, Buss Perry, and Barratt Aggression scores was done using the Kruskal-Wallis test. Analysis was done using SPSS version 21 software (IBM Corp. Armonk, NY). Missing value imputation was not required, and the p-value for the comparisons was set at 0.05.

Results

A total of 437 patients with opioid dependence were recruited for the study, of which 366 were included in the analysis. Others were excluded as either the sample collected was too little for the genetic analysis or they were currently dependent on other substances as well (apart from tobacco). The characteristics of the patients included in the study are presented in Table 1. All the patients with opioid dependence were males, and the mean age was 33.9 (±12.5). Current dependent use of tobacco was present in about three-fifths of the population. The sample comprised predominantly heroin users, though a substantial proportion comprised of raw opium/poppy husk users as well. About six percent of the sample was injecting drug users. A total of 200 controls were recruited.
### TABLE 1: Demographic characteristics of opioid dependence patients and behavioral parameters

*p < 0.05; Mean (±Standard deviation) or frequency (percentage), †Those with current dependent use were excluded

| Variable                        | Overall (n = 366) | With a history of self-harm or suicide attempt (n = 61) | Without a history of self-harm or suicide attempt (n = 305) | Comparison (p-value) |
|---------------------------------|-------------------|--------------------------------------------------------|-----------------------------------------------------------|---------------------|
| Age in years                    | 33.9 (±12.5)      | 27.1 (±9.2)                                            | 35.3 (±12.7)                                              | t = 5.876 (0.001)*  |
| Married currently               | 215 (58.7)        | 25 (41.0)                                              | 190 (62.1)                                                | $\chi^2$ = 8.667 (0.003)* |
| Currently employed              | 306 (83.1)        | 50 (82.0)                                              | 254 (83.0)                                                | $\chi^2$ = 0.662 (0.803) |
| Education up to high school     | 290 (79.2)        | 51 (83.6)                                              | 239(78.4)                                                 | $\chi^2$ = 0.561 (0.454) |
| Urban residence                 | 208 (56.8)        | 44 (72.1)                                              | 164 (53.6)                                                | $\chi^2$ = 6.985 (0.008)* |
| Heroin user                     | 226 (61.7)        | 55 (90.2)                                              | 166 (54.4)                                                | $\chi^2$ = 25.666 (0.001)* |
| Injecting drug use              | 22 (6.0)          | 3 (4.9)                                                | 19 (6.2)                                                  | $\chi^2$ = 0.010 (0.922) |
| Barratt Impulsiveness Scale     |                   |                                                        |                                                          |                     |
| Attentional                     | 15.9 (±2.3)       | 17.2 (±2.2)                                            | 15.7 (±2.2)                                              | t = 4.789 (0.001)*  |
| Motor                           | 20.6 (±2.8)       | 20.7 (±2.7)                                            | 20.6 (±2.8)                                              | t = 0.297 (0.763)   |
| Non-plan                        | 27.0 (±3.6)       | 28.7 (±3.4)                                            | 26.7 (±3.5)                                              | t = 4.199 (0.001)*  |
| Buss Perry Aggression Questionnaire |                 |                                                        |                                                          |                     |
| Physical                        | 23.0 (±6.2)       | 25.7 (±5.8)                                            | 22.4 (±6.1)                                              | t = 3.850 (0.001)*  |
| Verbal                          | 11.8 (±4.3)       | 13.6 (±4.3)                                            | 11.4 (±4.3)                                              | t = 3.646 (0.001)*  |
| Anger                           | 18.5 (±4.6)       | 20.5 (±3.6)                                            | 18.1 (±4.6)                                              | t = 4.414 (0.001)*  |
| Hostility                       | 16.1 (±5.1)       | 18.4 (±4.7)                                            | 15.7 (±5.1)                                              | t = 3.832 (0.001)*  |
| Hamilton Depression Rating Scale | 2.2 (±2.2)        | 3.7 (±2.2)                                             | 2.0 (±2.1)                                               | t = 5.784 (0.001)*  |

The parameters on the Hamilton Depression Rating Scale, Barratt Impulsiveness Scale, and Buss Perry Aggression Questionnaire are presented in Table 1. It was seen that 61 participants, i.e., 16.7% of the sample had a history of self-harm or suicide attempts. Among these, 38 participants had a history of self-harm without intent to die, and 35 participants had a history of suicide attempts with intent to die. This reflects that 12 participants had a history of suicide attempts with intent to die and self-harm without intent on different occasions.

The genotype and allele frequencies of the 5’HTTLPR, STin2 VNTR, TPH1(A218C), and TPH2(G703T) polymorphisms are shown in Table 2. There was no deviation from Hardy Weinberg Equilibrium for 5’HTTLPR, TPH1, and TPH2. There was a significant difference of 5’HTTLPR in the genotype and allele...
frequencies between opioid-dependent cases and controls while other polymorphisms like STin2 VNTR, TPH1 (A218C), and TPH2(G703T) did not show any difference.

| Marker       | Genotypic distribution (frequencies) | Allelic distribution (frequencies) |
|--------------|-------------------------------------|----------------------------------|
|              | p-value                             | p-value                          |
| 5-HTTLPR     | S/S 137 (37.4%)                     | S 438 (59.8%)                    |
|              | S/L 164 (44.8%)                     | L 294 (40.1%)                    |
|              | L/L 65 (17.8%)                      |                                 |
|              | <0.001*                             | 0.001*                           |
| cases        |                                    |                                  |
| controls     | 43 (22.0%)                          | 201 (50.2%)                      |
|              | 115 (57.0%)                         | 199 (49.7%)                      |
|              | 42 (21.0%)                          |                                  |
| STin2 VNTR   | 10/10 80 (21.9%)                    | 10 287 (39.2%)                   |
|              | 10/12 127 (34.7%)                   | 12 445 (60%)                     |
|              | 12/12 159 (43.4%)                   |                                  |
| cases        |                                      | 0.935                            |
| controls     | 42 (21.0%)                          | 152 (38%)                        |
|              | 68 (34.0%)                          | 248 (62%)                        |
|              | 90 (45.0%)                          |                                  |
| TPH1         | C/C 179 (48.9%)                     | C 499 (68.2%)                    |
|              | C/T 141 (38.5%)                     | T 233 (31.8%)                    |
|              | T/T 46 (12.5%)                      |                                  |
| cases        | 108 (54.0%)                         | 284 (71.4%)                      |
| controls     | 68 (34.0%)                          | 116 (28.5%)                      |
|              | 24 (12.0%)                          |                                  |
| TPH2         | G/G 193 (52.7%)                     | G 533 (72.8%)                    |
|              | G/T 147 (40.2%)                     | T 199 (27.2%)                    |
|              | T/T 26 (7.1%)                       |                                  |
| cases        |                                      | 0.475                            |
| controls     | 76 (38.0%)                          | 304 (76.0%)                      |
|              | 10 (5.0%)                           | 96 (24.0%)                       |

TABLE 2: Genotype and allele frequencies in patients with opioid dependence (n = 366)

*Significant at p < 0.05

The short allele of 5-HTTLPR polymorphism showed a significantly higher frequency in cases (59.8%) compared to controls (40.1%) (p=0.001). It was found that age at opioid dependence in cases with 5-HTTLPR was higher with SS (short allele) 24.00(20.00-30.00) as compared to LL (long allele) 22.00(19.00-27.00) and SL 21.0(18.00-26.00) genotypes (p=0.033). Further, the pair-wise comparison revealed the 5-HTTLPR SS genotype to be associated with higher opioid age of dependence as compared to SL genotypes (p=0.012) while 5-HTTLPR also showed an association with the duration of opioid use (p=0.061) and the Barratt non-plan impulsivity score (p=0.076) but did not reach statistical significance (Table 3).
The values in each cell are represented as median (Interquartile range). *Significant at 5% level

TABLE 3: Association of marker genotypes with opioid use parameters

The values in each cell are represented as median (Interquartile range). *Significant at 5% level

| STin2 VNTR | 12/12 (18.00-26.00) | 23.00 (19.00-26.50) | 3.00 (2.00-5.00) | 22.00 (18.00-26.00) | 12.00 (8.00-15.00) | 19.00 (15.00-22.00) | 16.00 (11.00-20.00) | 16.00 (14.00-18.00) | 21.00 (19.00-24.00) | 27.00 (24.00-29.00) | 2.00 (0.00-4.00) |
|------------|---------------------|--------------------|-----------------|---------------------|--------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|            | P-value             | 0.836              | 0.752           | 0.503               | 0.320              | 0.624               | 0.034*              | 0.525               | 0.668               | 0.471               | 0.592               | 0.464               |
| TPH1 A218C | 22.00 (19.00-27.00) | 23.00 (19.00-27.00)| 4.00 (2.00-7.00)| 22.00 (18.00-28.00)| 11.00 (8.25-16.00)| 19.00 (15.00-22.00)| 17.00 (13.00-20.00)| 16.00 (14.00-18.00)| 21.00 (19.00-22.00)| 27.00 (24.00-29.75)| 2.00 (0.00-4.00)  |
| A/C        | 20.00 (18.00-27.00)| 22.00 (19.00-27.00)| 3.00 (1.00-5.00)| 23.50 (8.00-15.00)| 12.00 (8.00-15.00)| 19.00 (15.00-22.00)| 16.00 (14.00-20.00)| 16.00 (14.00-18.00)| 21.00 (19.00-22.00)| 26.00 (24.00-29.00)| 2.00 (0.00-4.00)  |
| C/C        | 20.00 (17.00-29.25)| 21.00 (18.00-33.00)| 3.00 (2.00-5.25)| 23.00 (16.00-28.00)| 10.00 (7.00-13.00)| 18.00 (13.50-21.50)| 14.00 (10.00-19.00)| 14.00 (10.00-17.00)| 20.00 (18.00-22.00)| 26.00 (24.00-29.00)| 1.00 (0.00-3.50)  |
| G/G        | 21.00 (18.00-26.00)| 22.00 (19.00-27.00)| 3.00 (2.00-5.00)| 23.00 (18.00-28.00)| 12.00 (8.00-15.00)| 19.00 (15.00-22.00)| 16.00 (14.00-20.00)| 16.00 (14.00-18.00)| 20.00 (19.00-22.00)| 27.00 (24.00-29.00)| 2.00 (0.00-4.00)  |
| G/T        | 22.00 (19.00-28.25)| 23.00 (20.00-29.00)| 3.00 (2.00-5.00)| 22.00 (18.00-28.00)| 11.00 (8.00-15.00)| 19.00 (15.00-22.00)| 16.00 (12.00-19.00)| 16.00 (14.00-17.00)| 21.00 (19.00-22.00)| 27.00 (25.00-29.00)| 2.00 (0.00-4.00)  |
| T/T        | 20.00 (17.00-23.75)| 21.00 (18.25-24.00)| 5.00 (3.00-5.95)| 23.50 (16.00-29.50)| 13.00 (11.00-16.00)| 20.50 (17.75-23.00)| 18.00 (13.00-20.00)| 16.00 (14.00-17.00)| 21.00 (19.00-23.00)| 26.00 (24.00-30.00)| 2.00 (0.00-5.00)  |
| P-value    | 0.281               | 0.287              | 0.193           | 0.672               | 0.318              | 0.248               | 0.588               | 0.553               | 0.492               | 0.696               | 0.742               |

STin2A polymorphism revealed an association with Buss Perry anger scores, which showed the 10/10 repeat genotype to be associated with median scores of 20.00 (interquartile range [IQR] 16.00-23.00) compared to scores of 10/12 repeats (median 18.00, IQR 14.75-22.00) and 12/12 repeats (median 19.00, IQR 15.00-22.00) (p=0.054). Further, the pair-wise comparison revealed STin2A '10/10' repeats to be associated with higher Buss Perry anger score as compared to '10/12' repeat genotypes (p=0.009) (Table 3).

Additionally, the relationship of self-harm with clinical data is presented in Table 1. It was seen that those individuals with a history of self-harm or suicide attempt were significantly younger than those who had not attempted. Also, they were less likely to be married, have urban residence, and be a heroin user. It was seen that those with a history of self-harm or suicide attempt were more likely to have more attentional and non-plan impulsivity, and have a greater extent of physical, verbal, anger, and hostility aggression.

**Discussion**

The present study reports on the association of 5HTTLPR, STin2, TPH1 (A218T), and TPH2 (G703T) polymorphisms of the serotonergic pathway with self-harm, depressive symptoms, impulsiveness, and aggression in opioid dependence. Results revealed an association of short allele of 5-HTTLPR polymorphism with opioid dependence and with the age of opioid dependence. The 10/10 repeat genotype of STin2A polymorphism has shown significant association with the Buss Perry anger score in opioid dependence, which may suggest a role of this polymorphism in aggressiveness. Demographically, the sample of the study consisted exclusively of males (females were excluded, as they comprised less than 2% of the treatment-seeking population at the center and we wanted to homogenize the sample). Though the main opioid being used by the study population was heroin, a considerable proportion of the participants were using natural opiates (raw opium and poppy husk). This pattern of use has been echoed in other clinic-based studies from India [30], but is quite different from the pattern of opioid consumption in the treatment-seeking population.
in other parts of the world [31-32].

The present study revealed the short allele of 5-HTTLPR has a significantly higher frequency in patients with opioid dependence compared to controls. Studies by Gerra et al. [33] and Wang et al. [34] also reported a significant association of 5-HTTLPR with opioid dependence, which is in concordance with our findings. According to a meta-analysis by Lin and Wu [35], the ‘S’ allele has been found to be more common in the opioid-dependent population. The ‘S’ allele has reduced transcriptional activity and is associated with impulsive behavior, suicidal attempts, and violent behavior. The present study also revealed the 5-HTTLPR ‘S’ allele to be associated with a higher age of opioid dependence (p=0.012), duration of opioid use (p=0.061), and non-plan impulsivity (p=0.076). The results of the present study suggest the ‘S’ allele of 5-HTTLPR polymorphism is associated with delayed use of opioids. Regular and problematic opioid use may occur much later though experimental use may occur initially due to impulsive behaviors. This suggests that the later age of onset of dependence (even with no significant difference in onset of use) may reflect the instability of the course of opioid use disorder before it becomes entrenched as regular dysfunctional use in the form of dependence. These findings are in concordance with other studies on alcohol dependence, which reported the association of the 5-HTTLPR ‘S’ allele with age, duration of use, gene interaction, and type of substance abuse [12,36-37].

Another marker studied is STin2 VNTR, present in intron 2 of the SLC6A4 gene. Though the frequency of STin2 VNTR in cases and controls was similar in the present study, which is also in concordance with previous studies, the 10/10 genotype shows a significant association with the Buss Perry anger score. Some studies have hypothesized the role of serotonin deficiency in human aggression and have identified reduced serotonergic tone associated with increased risk for aggression [38-40]. In 2018, Hemnings et al. also report STin2 variants as an important regulator of aggression [41]. Therefore, the present study validates the previous reports suggesting an association of STin2 10/10 genotype with aggressiveness in opioid dependence.

The other two markers screened in the present study are A218C and G703T of the TPH1 and TPH2 genes, respectively. The polymorphism A218C is located at a potential GATA transcription factor-binding site and is reported to affect the expression of the TPH1 gene [42]. Studies have revealed the association of TPH1 A218C with impulsivity, suicidality [43], and opiate dependence [44]. TPH2 G703T has been linked to psychiatric disorders such as alcohol dependence, schizophrenia, and major depression [18-20], leading to serious conditions like suicidal risks. However, in the present study, no such association of A218C and G703T polymorphisms was identified with opioid dependence.

Other findings of the study were that suicide attempts and self-harm behaviors in patients with opioid dependence were associated with clinical predictors like younger age, being unmarried, having an urban residence, and being a heroin user. Furthermore, opioid dependence patients with a suicide attempt history were found to have high rates of impulsiveness and aggression when compared to opioid dependence patients without such a history. The results are in concordance with previous studies, which suggested a relationship between impulsiveness and self-harm behavior among young adults and adolescents [45-46]. This is possibly contributed by risky decision-making and deficits in inhibitory control or may be due to undiagnosed attention deficit hyperactivity disorder (ADHD). Aggression has also been associated with self-harm attempts in general. There is evidence to support that aggression and anger are linked to suicidal attempts in substance-using populations [47-48].

The strengths of the present study lie in having a fairly large sample size, using Indian ethnicity, which has not been frequently reported in the published literature, and looking at clinical determinants like impulsiveness and aggression in addition to the serotonin pathway gene polymorphisms. The limitations of the study include a single-center sample from northern India rather than using multiple sites, a clinic-based sample rather than a community sample, and assessing only four genetic polymorphisms. Assessment of self-harm and suicide attempt, impulsiveness, and aggression was based upon self-report from the patients. The lifetime history of suicide or self-harm attempt was considered instead of imposing a time frame, and it does not preclude the likelihood of an attempt in the future.

Conclusions

To the best of our knowledge, this is the first report on the association of 5HTTLPR, STin2, TPH1 (A218T), and TPH2 (G703T) polymorphisms in opioid dependence in the Indian population, in which the SLC6A4 5HTTLPR and STin2 VNTR have shown an association with opioid dependence and aggressiveness respectively among the patients. The study of these markers may help in a better understanding of the neurobiology of opioid dependence and its relation with aggression and impulsiveness. Impulsiveness and aggression are common phenotypic expressions associated with opioid dependence and in those with self-harm attempts. Understanding which risk alleles relate to increased chances of aggression and impulsivity may lead to more focussed attempts to address these using psychotherapeutic, and possibly pharmacological means.

Appendices
Genetic analysis

A reaction mixture of 25 µl was prepared using 200 ng genomic DNA, specific primers (0.5 µM each), MgCl2 (1.5 mM), deoxynucleoside triphosphates (dNTPs; 0.2 mM), 1× PCR buffer (Thermofisher Scientific, Waltham, Massachusetts), and Taq polymerase (0.5 U; Thermofisher Scientific) in a thermocycler (ABI 9700, [ABI], Foster City, CA). PCR cycling conditions were 7 min initial denaturation at 95 °C, followed by 35 cycles of 94 °C for 30 s, 55 °C–64 °C for 1 min, 72 °C for 1 min, and a final extension at 72 °C for 10 min. The amplified products were genotyped using PCR-restriction fragment length polymorphism (RFLP), and the alleles were scored. One marker TPH1(A218C) was screened using the TaqMan Genotyping assay using primers designed by the manufacturer (Thermofisher Scientific) and TaqMan Universal PCR Master Mix in Step One plus thermocycler using standard conditions (Applied Biosystems, Waltham, Massachusetts).

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institute Ethics Committee, All India Institute of Medical Sciences, New Delhi issued approval IEC-468/07.10.2016, RP-17/2016. The study was in accordance with the declaration of Helsinki and was approved by the institutional ethics committee. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The work was supported by Early Career Researcher Grant of the Department of Science and Technology, Government of India. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Merikangas KR, McClair VL: Epidemiology of substance use disorders. Hum Genet. 2012, 131:779-89. 10.1007/s00439-012-1168-0
2. World drug report 2015. (2020). Accessed: December 16, 2020: https://www.unodc.org/wdr2015/.
3. The extent, pattern and trends of drug abuse in India: National Survey. Ministry of Social Justice and Empowerment, Government of India & United Nations Office on Drugs and Crime, Regional Office for South. (2004). Accessed: October 18, 2021: https://www.unodc.org/pdf/india/presentations/india_national_survey_2004.pdf.
4. Group of Investigators for the National Survey on Extent and Pattern of Substance Use In India. Magnitude of substance use in India 2019. (2019). Accessed: October 18, 2021: https://socialjustice.nic.in/writereaddata/UploadFile/Magnitude_Substance_Use_India_REPORT.pdf.
5. Rehm J, Taylor B, Room R: Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006, 25:503-15. 10.1080/09595230600944455
6. Hatton K, Saunders K, Topiwala A, Haw C: Psychiatric disorders in patients presenting to hospital following self-harm: a systematic review. J Affect Disord. 2015, 151:821-30. 10.1016/j.jad.2015.08.020
7. Heinz AJ, Makin-Byrd K, Blonigen DM, Reilly P, Timko C: Aggressive behavior among military veterans in substance use disorder treatment: the roles of posttraumatic stress and impulsivity. J Subst Abuse Treat. 2015, 50:59-66. 10.1016/j.jsat.2014.10.014
8. Larkin C, Di Blasi Z, Arensman E: Risk factors for repetition of self-harm: a systematic review of prospective hospital-based studies. PLoS One. 2014, 9:e84282. 10.1371/journal.pone.0084282
9. Lyngdoh M, Akoijam BS, S Agui RK, Sonarjit Singh K: Sleep pattern, aggressive behavior and substance use among school students of Manipur: a cross-sectional study. Indian J Public Health. 2019, 63:259-42. 10.4103/ijph.IJPH_334_18
10. Wilcox HC, Conner KR, Caine ED: Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend. 2004, 76 Suppl S11-9. 10.1016/j.drugalcdep.2004.08.003
11. Bleich S, Bönsch D, Rauh J, Bayerlein K, Fiszer R, Frieling H, Hillemacher T: Association of the long allele of the 5-HTTLPR polymorphism with compulsive craving in alcohol dependence. Alcohol Alcohol. 2007, 42:509-12. 10.1095/alcage/40m006
12. van der Zwaluw CS, Engels RC, Vermulst AA, et al.: A serotonin transporter polymorphism (5-HTTLPR) predicts the development of adolescent alcohol use. Drug Alcohol Depend. 2010, 112:153-9. 10.1016/j.drugalcdep.2010.06.001
13. Heinz A, Jones DW, Mazzanti C, et al.: A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry. 2000, 47:643-9. 10.1016/s0006-3223(99)00171-7
14. Mackenzie A, Quinn J: A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A. 1999, 96:15251-5. 10.1073/pnas.96.26.15251
15. Caspi A, Sugden K, Moffitt TE, et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003, 301:536-9. 10.1126/science.1085968
16. Lesch KP, Bengel D, Heils A, et al.: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996, 274:1527-51. 10.1126/science.274.5292.1527
17. Bah J, Lindström M, Westberg L, et al.: Serotonin transporter gene polymorphisms: effect on serotonin transporter availability in the brain of suicide attempters. Psychiatry Res. 2008, 162:221-9.
18. Lehto K, Vaht M, Mäestu J, Veidebaum T, Harjo J: Effect of tryptophan hydroxylase-2 gene polymorphism G-703 T on personality in a population representative sample. Prog Neuropsychopharmacol Biol Psychiatry. 2015, 57:51-5. 10.1016/j.pnpbp.2014.10.005

19. Stefufj, Mokrovic G, Hramilovic D, Boudakalo-Knisic T, Bakula M, Kubat M, Jeremy B: Functional promoter polymorphism of the neuronal isoform of tryptophan hydroxylase (Tph2) in suicide. Psychiatry Res. 2011, 186:446-7. 10.1016/j.psychres.2010.08.034

20. Zhou Z, Roy A, Lipsky R, et al.: Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry. 2005, 62:1109-18. 10.1001/archpsyc.62.11.1109

21. Waidner J, Proff F, Langhofer G, Asan E, Lesch KP, Gatknecht L: GABA concentration and GABAergic neuron populations in limbic areas are differentially altered by brain serotonin deficiency in Tph2 knock out mice. Histochm Cell Biol. 2015, 139:267-81. 10.1007/s00418-012-1029-x

22. Handelsman L, Cochrane KJ, Aronson MJ, Niss R, Rubinstein KJ, Kanof PD: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987, 13:293-308. 10.3109/00952987090011515

23. Sheehan DV, Lecrubier Y, Sheehan KJ, et al.: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998, 59:22-33.

24. Hamilton M: A rating scale for depression. J Neurosurg Psychiatry. 1960, 23:56-62. 10.1136/jnnp.23.1.56

25. Patton JH, Stanford MS, Barratt ES: Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995, 51:768-74. 10.1002/1097-4679(199511)51:6<768::AID-JCPS2270510607>3.0.CO;2-1

26. Buss AH, Perry M: The aggression questionnaire. J Pers Soc Psychol. 1992, 63:452-9. 10.1037/0022-3514.63.3.452

27. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215. 10.1093/nar/16.3.1215

28. Fromme K, de Wit H, Hutchison KE, et al.: Biological and behavioral markers of alcohol sensitivity. Alcohol Clin Exp Res. 2004, 28:247-56. 10.1097/01.acb.0000113420.28472.25

29. Martinez-Barrondo S, Saiá PA, Morales B, García-Portilla MP, Coto E, Álvarez V, Bobes J: Serotonin gene polymorphisms in patients with panic disorder. Acta Psychiatr Scand. 2005, 112:39-45.

30. Basu D, Aggarwal M, Das PP, Mattoo SK, Kulhara P, Varma VK: Changing pattern of substance abuse in patients attending a de-addiction centre in north India (1978-2008). Indian J Med Res. 2012, 135:830-6.

31. Nielsen S, Bruno R, Lintzeris N, Fischer J, Stoove M: Pharmacological opioid analgesic and heroin dependence: how do treatment-seeking clients differ in Australia? Drug Alcohol Rev. 2011, 30:291-9. 10.1111/j.1465-3362.2011.00302.x

32. Subramaniam GA, Stitzer MA: Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend. 2009, 101:153-9. 10.1016/j.drugalcdep.2008.10.015

33. Gerra G, Garofano L, Santoro G, et al.: Association between low-activity serotonin transporter genotype and heroin dependence: behavioral and personality correlates. Am J Med Genet B Neuropsychiatr Genet. 2004, 128B:37-42. 10.1002/ajmg.b.20111

34. Wang TY, Lee SY, Chen SL, et al.: Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. Behav Brain Res. 2015, 250:285-92. 10.1016/j.bbr.2015.05.015

35. Lin PY, Wu YS: Association between serotonin transporter gene polymorphisms and heroin dependence: a meta-analytic study. Neuropsychiatr Dis Treat. 2016, 12:3061-7. 10.2147/NPD.T.210786

36. Oo KZ, Aung YK, Jenkins MA, Win AK: Associations of SHTTLPR polymorphism with major depressive disorder and alcohol dependence: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2016, 50:842-57. 10.1177/0004867416635790

37. Sahni S, Tickoo M, Gupta R, Vaswani M, Ambekar A, Grover T, Sharma A: Association of serotonin and GABA pathway gene polymorphisms with alcohol dependence: a preliminary study. Asian J Psychiatry. 2019, 39:169-73. 10.1016/j.ajp.2018.04.023

38. Alenina N, Kikic D, Todiras M, et al.: Growth retardation and altered autonomic control in mice lacking brain serotonin. Proc Natl Acad Sci U S A. 2009, 106:10332-7. 10.1073/pnas.0810795106

39. Audero E, Milnar B, Baccini G, Skachkova ZK, Corradetti R, Gross C: Suppression of serotonin neuron firing increases aggression in mice. J Neurosci. 2015, 35:8678-88. 10.1523/NEUROSCI.2067-12.2013

40. Mosenko V, Bert B, Beis D, Matthys S, Fink H, Bader M, Alenina N: Exaggerated aggression and decreased anxiety in mice deficient in brain serotonin. Transl Psychiatry. 2012, 2:e212. 10.1038/tp.2012.44

41. Hemmings SM, Xulu K, Sommer J, et al.: Appetitive and reactive aggression are differentially associated with the STIN2 genetic variant in the serotonin transporter gene. Sci Rep. 2018, 8:6714. 10.1038/s41598-018-25066-8

42. Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D: Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res. 1997, 57:51-5. 10.1016/S0169-328X(96)00054-x

43. Nielsen DA, Goldman D, Vrirkunen M, Tokola R, Rawlings R, Linnola M: Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry. 1994, 51:54-8. 10.1001/archpsyc.1994.03950010054005

44. ZB P, Freuss UW, Koller G, Budy R, Soyka M: SNP- and haplotype analysis of the tryptophan hydroxylase 2 gene in alcohol-dependent patients and alcohol-related suicide. Neuropsychopharmacology. 2007, 32:1687-94. 10.1038/sj.npp.1301318

45. Lockwood J, Daley D, Townsend E, Sayal K: Impulsivity and self-harm in adolescence: a systematic review. Eur Child Adolesc Psychiatry. 2017, 26:387-402. 10.1007/s00787-016-0915-5

46. McHugh CM, Chun Lee RS, Hermens DF, Corderoy A, Large M, Hickie IB: Impulsivity in the self-harm and suicidal behavior of young people: a systematic review and meta-analysis. J Psychiatr Res. 2019, 116:51-60.
47. Doihara C, Kawanishi C, Yamada T, et al.: Trait aggression in suicide attempters: a pilot study. Psychiatry Clin Neurosci. 2008, 62:352-4. 10.1111/j.1440-1819.2008.01804.x

48. Evren C, Cinar O, Evren B, Celik S: History of suicide attempt in male substance-dependent inpatients and relationship to borderline personality features, anger, hostility and aggression. Psychiatry Res. 2011, 190:126-31. 10.1016/j.psychres.2011.08.002